TLDR
- ISRG posts 19% revenue growth as robotic surgery demand accelerates in Q2
- Intuitive lifts earnings and system placements despite after-hours stock drop
- Da Vinci and Ion procedure growth powers strong Intuitive Q2 performance
- ISRG expands installed base while reporting record quarterly revenue growth
- Intuitive maintains 2026 outlook after delivering robust second-quarter results
Intuitive Surgical, Inc. (ISRG) shares closed at $402.33, up 3.43% before plunging 10.52% after hours despite strong second-quarter 2026 results and higher revenue. The company delivered $2.89 billion in quarterly revenue, while robotic surgery demand continued expanding worldwide. Intuitive increased system placements and strengthened its installed base across hospitals.
Intuitive Surgical, Inc., ISRG
Q2 Results Show Strong Revenue and Profit Growth
Intuitive Surgical generated $2.89 billion in Q2 2026 revenue, marking a 19% increase from $2.44 billion. Furthermore, higher procedure volumes and increased system leasing revenue supported the quarterly growth. The company also benefited from a larger installed base of da Vinci and Ion systems.
The company recorded GAAP net income of $818 million, or $2.29 per diluted share, during the quarter. Non-GAAP net income reached $1 billion, or $2.80 per diluted share. Both results exceeded the previous year’s quarterly figures of $658 million and $800 million.
Additionally, Intuitive reported higher operating performance as GAAP operating income reached $972 million. The company increased non-GAAP operating income to $1.22 billion from $950 million. The business maintained strong profitability while expanding its robotic surgery operations.
Robotic Surgery Systems Expand Across Global Healthcare Markets
Intuitive placed 468 da Vinci surgical systems during Q2 2026 compared with 395 systems a year earlier. 246 placements involved the newer da Vinci 5 systems, compared with 180 previously. The company also placed 55 Ion endoluminal systems during the quarter.
The company expanded its da Vinci installed base to 11,710 systems by June 30, 2026. This represented a 12% increase from 10,488 systems recorded during the same period. The Ion installed base grew 21% to 1,096 systems.
Worldwide procedures using da Vinci and Ion systems increased approximately 16% year over year. Da Vinci procedures grew 15%, while Ion procedures increased 36%. These gains reflected continued adoption of minimally invasive surgical technologies.
Intuitive Maintains 2026 Outlook After Strong Quarterly Performance
Intuitive Surgical ended Q2 2026 with $8.63 billion in cash, cash equivalents, and investments. The balance increased by $650 million during the quarter, supported mainly by operating cash generation.Share repurchases reduced part of the available cash growth.
The company repurchased 900,000 shares during the quarter for approximately $380 million. Intuitive highlighted continued investment in digital solutions and robotic healthcare platforms. Hence, the company continues building its position in minimally invasive care.
For full-year 2026, Intuitive expects worldwide da Vinci procedure growth between 13.5% and 15.5%. The company also expects non-GAAP gross profit margins between 68% and 69% of revenue. O
perating expenses are projected to grow between 11% and 13% during 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
